|
KMID : 1134120220250010069
|
|
Journal of Breast Cancer
2022 Volume.25 No. 1 p.69 ~ p.73
|
|
|
The Prediction of HER2-Targeted Treatment Response Using 64Cu-Tetra-Azacyclododecanetetra-Acetic Acid (DOTA)-Trastuzumab PET/CT in Metastatic Breast Cancer: A Case Report
|
|
Lee In-Ki
Lim Il-Han
Byun Byung-Hyun
Kim Byung-Il
Choi Chang-Woon
Lee Kyo-Chul
Kang Choong-Mo
Seong Min-Ki
Kim Hyun-Ah
Noh Woo-Chul
Lim Sang-Moo
|
|
|
Abstract
|
|
|
|
A 45-year-old woman diagnosed with breast cancer reported disease progression in the form of metastatic lung and recurrent breast lesions following chemotherapy and human epidermal growth factor receptor 2 (HER2)-targeted therapy. The patient underwent 64Cu-tetra-azacyclododecanetetra-acetic acid (DOTA)-trastuzumab positron emission tomography/computed tomography (PET/CT) to evaluate the HER2 expression status. 64Cu-DOTA-trastuzumab accumulated in the left breast and lymph nodes but not in the lung lesions. Following trastuzumab emtansine treatment, there was a significant improvement in the lesions with 64Cu-DOTA-trastuzumab accumulation. However, the lesions that did not accumulate 64Cu-DOTA-trastuzumab aggravated. Therefore, it was concluded that 64Cu-DOTA-trastuzumab PET/CT can be used to predict the outcome of HER2-targeted treatment by evaluating HER2 expression in breast cancer patients.
|
|
|
KEYWORD
|
|
|
Breast Neoplasms, 64Cu-DOTA-Trastuzumab, ERBB2 Protein, Human, Positron-Emission Tomography
|
|
|
FullTexts / Linksout information
|
|
|
|
|
Listed journal information
|
|
   
|